Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:FUSN Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Fusion Pharmaceuticals Stock (NASDAQ:FUSN) 30 days 90 days 365 days Advanced Chart Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Fusion Pharmaceuticals alerts:Sign Up Key Stats Today's Range$21.55▼$21.5550-Day Range$21.38▼$21.5552-Week Range$2.31▼$21.60VolumeN/AAverage Volume1.69 million shsMarket Capitalization$1.83 billionP/E RatioN/ADividend YieldN/APrice Target$20.25Consensus RatingHold Company OverviewFusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Read More… Receive FUSN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address FUSN Stock News HeadlinesFusion Finance Ltd (FUSN)November 5, 2024 | investing.comJapan start-up aims to launch world's first steady-state fusion reactor in 2034August 31, 2024 | msn.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.December 24, 2024 | Insiders Exposed (Ad)Fusion Pharma (FUSN) Earnings Dates & ReportsAugust 7, 2024 | investing.comAcquisition of Fusion Pharmaceuticals CompletedJune 4, 2024 | prnewswire.comFusion Pharmaceuticals Receives Final Court Order Approving ArrangementMay 31, 2024 | prnewswire.comFusion Pharmaceuticals Shareholders Approve Acquisition by AstraZenecaMay 29, 2024 | prnewswire.comFusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate CancerMay 9, 2024 | prnewswire.comSee More Headlines FUSN Stock Analysis - Frequently Asked Questions How were Fusion Pharmaceuticals' earnings last quarter? Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) released its earnings results on Tuesday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.58) by $0.13. The business had revenue of $0.33 million for the quarter. Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative trailing twelve-month return on equity of 48.74%. When did Fusion Pharmaceuticals IPO? Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What other stocks do shareholders of Fusion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW). Company Calendar Last Earnings11/09/2021Today12/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FUSN CUSIPN/A CIK1805890 Webfusionpharma.com Phone289-799-0891FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$20.25 High Stock Price Target$24.00 Low Stock Price Target$15.00 Potential Upside/Downside-6.0%Consensus RatingHold Rating Score (0-4)2.07 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,900,000.00 Net Margins-4,136.55% Pretax Margin-5,084.07% Return on Equity-48.74% Return on Assets-36.87% Debt Debt-to-Equity Ratio0.21 Current Ratio10.64 Quick Ratio10.64 Sales & Book Value Annual Sales$2.07 million Price / Sales885.53 Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book7.02Miscellaneous Outstanding Shares85,060,000Free Float78,468,000Market Cap$1.83 billion OptionableOptionable Beta-0.69 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:FUSN) was last updated on 12/24/2024 by MarketBeat.com Staff From Our Partners"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
